Pharma investment in UK picks up Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

M T W Thu F 10 September, 2026

AI has stopped being a question and started being an answer. Remaking workforces, AI-derived molecules into the clinic, catching record capital against sharpening doubt. What does it mean for biopharma? Find out, join us.

news BridgeBio Oncology slides as it tightens the scope of its KRAS program Pharma investment in UK picks up after last year’s lull, trade group says Encoded closes $275M Series F for Dravet syndrome drug

Sep 10 11:00 am ET Inside the IDMO model: Analytical comparability, regulatory readiness and operational excellence sponsored by Cellares Sep 16 2:00 pm ET Beyond ICD codes: Unlocking rare disease insights with genomics and claims-based data sponsored by GeneDx Sep 22 12:00 pm ET The future of drug pricing: Medicare negotiation, MFN models & beyond sponsored by ADVI Oct 15 1:00 pm ET Insights into Polycystic Kidney Disease: The Potential of Clinicogenomic Data Oct 20 11:00 am ET Intelligent oversight and orchestration: How mission control is redefining R&D decision-making sponsored by ZS Oct 22 11:00 am ET A new model for clinical research – Expanding community trial access sponsored by Parexel

One night, one room: the founders, scientists and investors behind the Endpoints 11, together in Boston this September. Reserve your spot now and save with the early bird rate.

Endpoints Pharma FDA should follow EMA's lead on drug rejection disclosures, researchers say ARPA-H selects companies to build AI tools for heart disease From lab banter to a Lasker Award: The science behind narcolepsy

in case you missed it 1. NodThera, a decade-old NLRP3 player, plans Phase 3 and a rebrand 2. Beeline Medicines reports promising mid-stage lupus data 3. Kura Oncology spins out diabetes pipeline with $50M and Lilly's help 4. News Briefing Compass posts positive psilocybin data; Solstice makes $225M debut 5. Tyra finds ray of sunshine in otherwise cloudy Phase 2 bladder cancer data 6. Exclusive: Cancer biotech TwoStep gets $62.5M to take twist on ADCs into clinic 7.